

A Review of the Toxicity of HIV Medications

Journal of Medical Toxicology

10, 26-39

DOI: [10.1007/s13181-013-0325-8](https://doi.org/10.1007/s13181-013-0325-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of HIV Infection in Patients With Cancer Receiving Chemotherapy. <i>Clinical Infectious Diseases</i> , 2014, 59, 106-114.	2.9	52
2	Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. <i>Journal of Hepatology</i> , 2014, 61, 502-507.	1.8	152
3	Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy. <i>SAR and QSAR in Environmental Research</i> , 2014, 25, 457-471.	1.0	17
4	Antiviral Natural Products and Herbal Medicines. <i>Journal of Traditional and Complementary Medicine</i> , 2014, 4, 24-35.	1.5	369
5	Evolving Human Rights and the Science of Antiretroviral Medicine. <i>Health and Human Rights</i> , 2015, 17, 76.	1.3	9
6	Modeling of Plasmodium falciparum Telomerase Reverse Transcriptase Ternary Complex: Repurposing of Nucleoside Analog Inhibitors. <i>Assay and Drug Development Technologies</i> , 2015, 13, 628-637.	0.6	1
7	Low abundance of mitochondrial DNA changes mitochondrial status and renders cells resistant to serum starvation and sodium nitroprusside insult. <i>Cell Biology International</i> , 2015, 39, 865-872.	1.4	5
8	Drug-Induced Metabolic Acidosis. <i>F1000Research</i> , 2015, 4, 1460.	0.8	29
9	Leptin expression in HIV-infected patients during antiretroviral therapy. <i>Germes</i> , 2015, 5, 92-98.	0.5	13
10	Overdose of dolutegravir in combination with tenofovir disoproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient. <i>AIDS Research and Therapy</i> , 2015, 12, 18.	0.7	9
11	A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. <i>Journal of Medical Toxicology</i> , 2015, 11, 326-341.	0.8	65
12	Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection. <i>Molecular Pharmaceutics</i> , 2015, 12, 4226-4236.	2.3	20
13	Successful Treatment of Mitochondrial Toxicity in an HIV-Positive Patient After Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2771-2774.	0.3	2
14	Effects of Combined Alcohol and Anti-HIV Drugs on Cellular Stress Responses in Primary Hepatocytes and Hepatic Stellate and Kupffer Cells. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 11-20.	1.4	19
15	Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4824-4827.	1.0	19
16	Investigational reverse transcriptase inhibitors for the treatment of HIV. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1219-1228.	1.9	11
17	Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41. <i>European Journal of Medicinal Chemistry</i> , 2015, 106, 34-43.	2.6	29
18	Economic Evaluation of Nevirapine plus Raltegravir as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1 Infected Patients. <i>Global & Regional Health Technology Assessment</i> , 2016, 3, GRHTA.5000217.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients. <i>World Journal of Nephrology</i> , 2016, 5, 33.	0.8	24
20	Dual therapy based on raltegravir and boosted protease inhibitors – the experience of Polish centers. <i>Archives of Medical Science</i> , 2018, 14, 860-864.	0.4	3
21	Therapeutic Drug Monitoring of Antiretrovirals. , 2016, , 135-163.		0
22	Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1287-1294.	1.0	5
23	Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 485-491.	0.9	42
25	Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity. <i>Scientific Reports</i> , 2016, 6, 39738.	1.6	41
26	Body – drug assemblages: theorizing the experience of side effects in the context of <scp>HIV</scp> treatment. <i>Nursing Philosophy</i> , 2016, 17, 250-261.	0.9	20
27	Current status and prospects of HIV treatment. <i>Current Opinion in Virology</i> , 2016, 18, 50-56.	2.6	249
28	Development of peptide inhibitors of HIV transmission. <i>Bioactive Materials</i> , 2016, 1, 109-121.	8.6	22
29	Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. <i>Jornal De Pediatria</i> , 2016, 92, 631-637.	0.9	5
30	Role of endoplasmic reticulum stress in drug-induced toxicity. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00211.	1.1	179
31	Recent trends on hydrogel based drug delivery systems for infectious diseases. <i>Biomaterials Science</i> , 2016, 4, 1535-1553.	2.6	54
32	Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. <i>Chemico-Biological Interactions</i> , 2016, 259, 407-412.	1.7	3
33	Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1113-1126.	2.0	6
34	Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. <i>Retrovirology</i> , 2016, 13, 11.	0.9	10
35	HIV, Viral Suppression and New Technologies of Surveillance and Control. <i>Body and Society</i> , 2016, 22, 82-107.	0.3	24
36	Abdominal Pain in the Immunocompromised Patient – Human Immunodeficiency Virus, Transplant, Cancer. <i>Emergency Medicine Clinics of North America</i> , 2016, 34, 377-386.	0.5	8
37	Dosing antiretroviral medication when crossing time zones. <i>Aids</i> , 2016, 30, 267-271.	1.0	7

#	ARTICLE	IF	CITATIONS
38	Drugs influencing acid base balance and bicarbonate concentration readings. Expert Review of Endocrinology and Metabolism, 2016, 11, 209-216.	1.2	3
39	Classification and Diagnosis of Diabetes Mellitus. , 2016, , 662-671.e2.		2
40	Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling. Interdisciplinary Sciences, Computational Life Sciences, 2017, 9, 406-418.	2.2	6
41	N ² -Substituted 2'-Deoxyguanosine Triphosphate Derivatives as Selective Substrates for Human DNA Polymerase Î. Angewandte Chemie - International Edition, 2017, 56, 2628-2631.	7.2	15
42	HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clinical Trials, 2017, 18, 67-74.	2.0	3
43	Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiology, 2017, 12, 141-155.	1.0	37
44	N ² -Substituted 2'-Deoxyguanosine Triphosphate Derivatives as Selective Substrates for Human DNA Polymerase Î. Angewandte Chemie, 2017, 129, 2672-2675.	1.6	2
45	Correlation of Leptin, Adiponectin, and Resistin Levels in Different Types of Lipodystrophy in HIV/AIDS Patients. Metabolic Syndrome and Related Disorders, 2017, 15, 153-159.	0.5	4
46	Lower levels of IL-4 and IL-10 influence lipodystrophy in HIV/AIDS patients under antiretroviral therapy. Experimental and Molecular Pathology, 2017, 102, 210-214.	0.9	5
47	Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. Scientific Reports, 2017, 7, 46344.	1.6	28
48	Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose. Therapeutic Drug Monitoring, 2017, 39, 91-92.	1.0	5
49	Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. Journal of Medical Virology, 2017, 89, 2122-2129.	2.5	9
50	Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid. Antiviral Research, 2017, 139, 32-40.	1.9	17
51	Dolutegravir and metformin. Aids, 2017, 31, 2176-2177.	1.0	8
52	Inherited mitochondrial genomic instability and chemical exposures. Toxicology, 2017, 391, 75-83.	2.0	26
53	In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals. Neurochemical Research, 2017, 42, 3220-3232.	1.6	23
54	Resistance Training as an Intervention for People Living With HIV/AIDS. Strength and Conditioning Journal, 2017, 39, 64-70.	0.7	2
55	A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical Pharmacokinetics, 2017, 56, 661-669.	1.6	27

#	ARTICLE	IF	CITATIONS
56	Multimorbidity and Burden of Disease. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2017, 42, 59-73.	2.6	19
57	Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: Potential contribution to HIV-associated neurocognitive disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 406-413.	1.8	19
58	An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	35
59	Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 17-31.	0.6	64
60	Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatmentâ€”Clinical Points of View and Practical Considerations. <i>Frontiers in Pharmacology</i> , 2017, 8, 831.	1.6	143
61	Anti-HIV Activities and Mechanism of 12-O-Tricosanoylphorbol-20-acetate, a Novel Phorbol Ester from <i>Ostodes katharinae</i> . <i>Molecules</i> , 2017, 22, 1498.	1.7	18
62	Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. <i>Infectious Diseases of Poverty</i> , 2017, 6, 163.	1.5	11
63	Impatto Economico Dei Regimi Semplificati a Base di Raltegravir Nel Trattamento di Mantenimento Dei Pazienti HIV-1 Infetti in Soppressione Virologica. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000266.	0.2	0
65	Conjugation of phosphonoacetic acid to nucleobase promotes a mechanism-based inhibition. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 384-389.	2.5	3
66	Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Induce Pathological Pain through Wnt5a-Mediated Neuroinflammation in Aging Mice. <i>Journal of Neuroimmune Pharmacology</i> , 2018, 13, 230-236.	2.1	35
67	Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. <i>Infectious Diseases</i> , 2018, 50, 352-360.	1.4	15
68	Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 732-737.	1.3	13
69	Neuropathy Associated with Drugs. , 0, , 151-155.		0
70	HIV infection and lipids. <i>Current Opinion in Cardiology</i> , 2018, 33, 429-435.	0.8	7
71	Drug-Induced Mitochondrial Toxicity. , 2018, , 269-295.		4
72	Intentional Overdose of Dolutegravir/Abacavir/Lamivudine (Triumeq) in a 26-Year-Old Man. <i>Antiviral Therapy</i> , 2018, 23, 549-552.	0.6	4
73	Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 322-326.	0.5	4
74	Frequent Occurrence of Pain and Prescription Opioid Use for Treatment of Pain Among Women with and at Risk for HIV Infection. <i>AIDS and Behavior</i> , 2018, 22, 2008-2017.	1.4	10

#	ARTICLE	IF	CITATIONS
75	Nucleoside reverse transcriptase inhibitorâ€reducing strategies in HIV treatment: assessing the evidence. <i>HIV Medicine</i> , 2018, 19, 18-32.	1.0	31
76	Correlation between total lymphocyte counts and CD4 among human immunodeficiency virus (HIV) patients. <i>MATEC Web of Conferences</i> , 2018, 197, 07002.	0.1	0
77	Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 877-887.	2.0	7
78	Acute kidney injury and other factors associated with mortality in hiv-infected patients. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2018, 64, 509-517.	0.3	1
79	Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats. <i>PLoS ONE</i> , 2018, 13, e0208537.	1.1	12
80	Metabolically Healthy or Metabolically Unhealthy Obese HIV-Infected Patients: Mostly a Matter of Age?. <i>Frontiers in Endocrinology</i> , 2018, 9, 681.	1.5	7
81	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1949-1954.	1.3	17
82	Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 561-570.	1.3	9
83	Hemochromatosis (<i>HFE</i>) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 942-949.	0.5	4
84	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
86	Clinical Pharmacology in HIV Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 435-444.	2.2	62
87	Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis. <i>Liver Research</i> , 2019, 3, 157-169.	0.5	22
88	<p>Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential</p>. <i>HIV/AIDS - Research and Palliative Care</i> , 2019, Volume 11, 179-192.	0.4	34
89	Metabolic plasticity of HIV-specific CD4+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. <i>Nature Metabolism</i> , 2019, 1, 704-716.	5.1	72
90	Peripheral neuropathy in patients with human immunodeficiency viral infection at a tertiary hospital in Ghana. <i>Journal of NeuroVirology</i> , 2019, 25, 464-474.	1.0	5
91	NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal. <i>Retrovirology</i> , 2019, 16, 17.	0.9	16
92	Diverse Effects of Small Molecule Inhibitors on Actin Cytoskeleton Dynamics in HIV-1 Infection. <i>Journal of Bacteriology and Virology</i> , 2019, 49, 69.	0.0	2
93	Mitochondrial dysfunctions in HIV infection and antiviral drug treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 1043-1052.	1.5	10

#	ARTICLE	IF	CITATIONS
94	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 728-734.	1.1	40
95	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019, 19, 59.	1.3	23
96	Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. <i>PLoS ONE</i> , 2019, 14, e0210476.	1.1	12
97	Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes. <i>Frontiers in Immunology</i> , 2019, 10, 914.	2.2	33
98	Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum. <i>Antiviral Research</i> , 2019, 168, 210-214.	1.9	9
99	Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. <i>HIV Research and Clinical Practice</i> , 2019, 20, 64-72.	1.1	15
100	Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers. <i>PLoS ONE</i> , 2019, 14, e0216712.	1.1	9
101	Mitochondrial Dysfunction Induced by Xenobiotics: Involvement in Steatosis and Steatohepatitis. , 2019, , 347-364.		1
102	Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24-week analysis (RIDAR) Tj ETQq0 0.0 rgBT /Overlock 10	0.3	0
103	Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. <i>Current HIV Research</i> , 2019, 16, 436-446.	0.2	22
104	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019, 70, 1222-1261.	1.8	629
105	HIV infection and latency induce a unique metabolic signature in human macrophages. <i>Scientific Reports</i> , 2019, 9, 3941.	1.6	74
106	Molecular docking study of lamellarin analogues and identification of potential inhibitors of HIV-1 integrase strand transfer complex by virtual screening. <i>Heliyon</i> , 2019, 5, e02811.	1.4	16
107	Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice. <i>Scientific Reports</i> , 2019, 9, 17158.	1.6	26
108	Probable hepatotoxicity with dolutegravir. <i>Aids</i> , 2019, 33, 1261-1263.	1.0	7
109	Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 885-892.	0.6	9
110	HPV-Associated Anal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 183-209.	0.2	41
111	Salvage Antiretroviral Therapy: Time for "DeNUKE"learization"? <i>Journal of Infectious Diseases</i> , 2020, 221, 1390-1393.	1.9	1

#	ARTICLE	IF	CITATIONS
112	Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 27-38.	0.5	8
113	Alteration of mitochondrial DNA homeostasis in drug-induced liver injury. <i>Food and Chemical Toxicology</i> , 2020, 135, 110916.	1.8	33
114	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020, 40, 6-17.	1.9	30
115	Comorbidities of HIV infection. <i>Aids</i> , 2020, 34, 1-13.	1.0	30
116	Polypharmacy in HIV: recent insights and future directions. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 126-133.	1.5	43
117	Cognitive impairment severity in relation to signs of subclinical Wernicke's encephalopathy in HIV and alcoholism comorbidity. <i>Aids</i> , 2020, 34, 391-403.	1.0	3
118	Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 349-368.	2.9	20
119	Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3327-3333.	1.3	12
120	HIV Associated Risk Factors for Ischemic Stroke and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5306.	1.8	18
121	Long-Term Low-Dose Delta-9-Tetrahydrocannabinol (THC) Administration to Simian Immunodeficiency Virus (SIV) Infected Rhesus Macaques Stimulates the Release of Bioactive Blood Extracellular Vesicles (EVs) that Induce Divergent Structural Adaptations and Signaling Cues. <i>Cells</i> , 2020, 9, 2243.	1.8	3
122	The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.	1.0	9
123	Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa356.	0.4	17
124	Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1. <i>Journal of Clinical Medicine</i> , 2020, 9, 2972.	1.0	6
125	"It made me more confident that I have it under control" Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. <i>PLoS ONE</i> , 2020, 15, e0232473.	1.1	7
126	Modulation of mTORC1 Signaling Pathway by HIV-1. <i>Cells</i> , 2020, 9, 1090.	1.8	24
127	Evaluation of 3-Dimensionality in Approved and Experimental Drug Space. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1292-1298.	1.3	35
129	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. <i>Frontiers in Genetics</i> , 2020, 11, 497.	1.1	13
130	The quest to slow ageing through drug discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 513-532.	21.5	260

#	ARTICLE	IF	CITATIONS
131	Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. Pharmaceuticals, 2020, 13, 122.	1.7	13
132	Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. Aids, 2020, 34, 790-793.	1.0	1
133	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. Journal of Infectious Diseases, 2022, 225, 1040-1049.	1.9	13
134	Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. Pharmaceuticals, 2020, 12, 171.	2.0	143
135	An activator of G protein-coupled receptor and MEK1/2-ERK1/2 signaling inhibits HIV-1 replication by altering viral RNA processing. PLoS Pathogens, 2020, 16, e1008307.	2.1	8
136	Recent Advances in the Development of Integrase Inhibitors for HIV Treatment. Current HIV/AIDS Reports, 2020, 17, 63-75.	1.1	22
137	Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population. Current Medical Research and Opinion, 2020, 36, 781-788.	0.9	14
138	Nanoparticle-Based Immunoengineered Approaches for Combating HIV. Frontiers in Immunology, 2020, 11, 789.	2.2	20
139	4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochemical Pharmacology, 2020, 177, 113937.	2.0	10
140	Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2502-2511.	2.0	2
141	Systemic Antiviral Agents. , 2021, , 114-125.e3.		0
142	Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero. Journal of Infectious Diseases, 2021, 223, 621-631.	1.9	10
143	Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. Chemical Biology and Drug Design, 2021, 97, 4-17.	1.5	8
144	Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-Mediated Viral Transcription. Virologica Sinica, 2021, 36, 254-263.	1.2	7
145	CNS Neurotoxicity of Antiretrovirals. Journal of NeuroImmune Pharmacology, 2021, 16, 130-143.	2.1	58
146	Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases, 2022, 75, 297-304.	2.9	8
147	Drugs Resistance and Treatment Failure in HIV and/or AIDS. , 2021, , 387-403.		0
148	Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
149	Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients. <i>Scientific Reports</i> , 2021, 11, 960.	1.6	30
150	Insomnia severity and depressive symptoms in people living with HIV and chronic pain: associations with opioid use. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 679-688.	0.6	10
151	Interventions to Improve Adherence to Antiretroviral Therapy (ART) in Sub-Saharan Africa: An Updated Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2477.	1.2	12
152	Mitochondrial changes associated with viral infectious diseases in the paediatric population. <i>Reviews in Medical Virology</i> , 2021, 31, e2232.	3.9	3
153	Repurposing Treatment of Wernickeâ€“Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. <i>Frontiers in Pharmacology</i> , 2020, 11, 598128.	1.6	17
154	The HIV reverse transcriptase Inhibitor Tenofovir suppressed DMH/HFDâ€“induced colorectal cancer in Wistar rats. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 940-954.	1.0	7
155	Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?. <i>Cells</i> , 2021, 10, 1212.	1.8	16
156	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. <i>Frontiers in Public Health</i> , 2021, 9, 690017.	1.3	26
157	HIV-Associated Anal Cancer. <i>Cureus</i> , 2021, 13, e14834.	0.2	3
158	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021, 14, 460.	1.7	2
159	Deciphering the association between HIV-specific immunity and immune reconstitution. <i>EBioMedicine</i> , 2021, 67, 103350.	2.7	2
160	Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan. <i>Value in Health Regional Issues</i> , 2021, 24, 216-223.	0.5	3
161	Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from <i>Candida albicans</i> â€“In Silico, In Vitro and In Vivo Approaches. <i>Journal of Fungi (Basel,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tt 50 257 Td		
162	Comparison of inÂˆvitro fertilization cycles in couples with human immunodeficiency virus type 1 infection versus noninfected couples through a retrospective matched case-control study. <i>F&S Reports</i> , 2021, 2, 376-385.	0.4	2
163	Mitochondrial DNA Instability Is Common in HIV-Exposed Uninfected Newborns. <i>Journal of Clinical Medicine</i> , 2021, 10, 2399.	1.0	1
164	The association between neutrophil to lymphocyte ratio and endothelial dysfunction in people living with HIV on stable antiretroviral therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 113-120.	2.0	3
165	Exploring New Scaffolds for the Dual Inhibition of HIV-1 RT Polymerase and Ribonuclease Associated Functions. <i>Molecules</i> , 2021, 26, 3821.	1.7	4
166	Association between frailty phenotype, quantification of plasma HIV-1 RNA, CD4 cell count and HAART in HIV-positive subjects: a systematic review and meta-analysis of observational studies. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 1159-1168.	0.6	3

#	ARTICLE	IF	CITATIONS
167	Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 891-903.	0.5	4
168	Estimating the effect of increasing dispensing intervals on retention in care for people with HIV in Haiti. <i>EClinicalMedicine</i> , 2021, 38, 101039.	3.2	5
169	Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients. <i>Biomedicines</i> , 2021, 9, 987.	1.4	1
170	Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. <i>Pharmaceutics</i> , 2021, 13, 1294.	2.0	9
172	Development and Validation of a Stability- Indicating RP-HPLC Method for the Simultaneous Estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2021, 18, 410-419.	0.6	5
173	The Role of Nanotechnology in Antiviral Regime: An Overview. <i>Nano LIFE</i> , 0, , 2130011.	0.6	1
174	<i>Drosophila</i> model of anti-retroviral therapy induced peripheral neuropathy and nociceptive hypersensitivity. <i>Biology Open</i> , 2021, 10, .	0.6	2
175	The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging. <i>Cells</i> , 2021, 10, 174.	1.8	63
176	Impact of pharmacological agents on mitochondrial function: a growing opportunity?. <i>Biochemical Society Transactions</i> , 2019, 47, 1757-1772.	1.6	31
177	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
178	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	1.3	62
180	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. <i>JCI Insight</i> , 2019, 4, .	2.3	6
181	Increased incidence of glaucoma medication usage in middle-aged Australian males taking antiretroviral medication â€“ a population-based study. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2020, 10, 30.	1.2	2
182	Gastrointestinal Symptoms in HIV-Infected Patients: Female Sex and Smoking as Risk Factors in an Outpatient Cohort in Brazil. <i>PLoS ONE</i> , 2016, 11, e0164774.	1.1	8
183	Dolabellane diterpenes from the Caribbean soft corals <i>Eunicea laciniata</i> and <i>Eunicea asperula</i> and determination of their anti HSV-1 activity. <i>Revista Colombiana De Quimica</i> , 2017, 46, 5.	0.2	7
184	Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. <i>Oncotarget</i> , 2017, 8, 106369-106381.	0.8	23
185	The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity. <i>Current Drug Metabolism</i> , 2016, 17, 648-662.	0.7	19
186	Paediatric antiretroviral overdose: A case report from a resource-poor area. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1094.	0.3	2

#	ARTICLE	IF	CITATIONS
187	Strength exercise for balance and gait in HIV-associated distal symmetrical polyneuropathy: A randomised controlled trial. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1268.	0.3	0
188	Precursors of Viral Proteases as Distinct Drug Targets. <i>Viruses</i> , 2021, 13, 1981.	1.5	11
189	Impact of Antiretroviral Therapy on Selected Metabolic Disorders – Pilot Study. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 539-549.	0.6	1
190	Central obesity & dyslipidemia in HIV patients on antiretroviral therapy. <i>Indian Journal of Medical Research</i> , 2018, 148, 366.	0.4	5
191	Functional capacity and ventilatory efficiency are preserved in well-controlled people living with human immunodeficiency virus/acquired immunodeficiency syndrome. <i>Journal of Exercise Rehabilitation</i> , 2018, 14, 680-687.	0.4	1
192	Effect of the duration of protease inhibitor therapy in HIV-infected individuals on the severity of obstructive sleep apnea. <i>Journal of Research in Medical Sciences</i> , 2019, 24, 65.	0.4	3
195	Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients. <i>Pharmaceutics</i> , 2021, 13, 1798.	2.0	17
196	Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 56-60.	0.5	0
198	"So far it's been choosing which side effects I want or I can deal with": A grounded theory of HIV treatment side effects among people living with HIV. <i>Aporia: the Nursing Journal</i> , 2016, 8, 19-40.	0.5	3
199	HIV-associated neurotoxicity and cognitive decline: Therapeutic implications. , 2022, 234, 108047.		12
200	Prescribing Contraindications and Cautions for HIV. <i>Journal for Nurse Practitioners</i> , 2021, , .	0.4	0
201	Chlorfenapyr Induce Oxidative Phosphorylation Deficiency in Exposed Rat and the Quinoa Effective Role. <i>Alexandria Science Exchange</i> , 2021, 42, 809-822.	0.0	0
202	Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, S34-S46.	0.9	8
203	IPSC-derived models in Africa: An HIV perspective. <i>Biochimie</i> , 2022, 196, 153-160.	1.3	1
204	A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti?. <i>BMC Health Services Research</i> , 2022, 22, 80.	0.9	2
206	Long-Term Trends in Comorbidity Evolution and Disease Burden in HIV-Positive Compared to HIV-Negative Individuals as They Age. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
207	Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0194121.	1.4	8
208	Chronic pain and infection: mechanisms, causes, conditions, treatments, and controversies. , 2022, 1, e000108.		17

#	ARTICLE	IF	CITATIONS
209	Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown. <i>Frontiers in Endocrinology</i> , 2022, 13, 814209.	1.5	7
210	Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis. <i>Viruses</i> , 2022, 14, 516.	1.5	3
211	Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX – a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine. <i>Journal of Virology</i> , 2022, 96, e0216121.	1.5	3
212	Physical Examination in Human Immunodeficiency Virus Disease. <i>Medical Clinics of North America</i> , 2022, 106, 527-536.	1.1	1
213	Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. <i>Diagnostics</i> , 2022, 12, 14.	1.3	3
214	The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment. <i>HIV Medicine</i> , 2022, 23, 611-619.	1.0	3
215	Effects of sub-chronic exposure of male albino rats to some insecticides on mitochondrial dysfunction and oxidative stress in the kidney with molecular docking. <i>Journal of Cellular Neuroscience and Oxidative Stress</i> , 2022, 13, .	0.1	2
234	Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model. <i>Pharmaceutics</i> , 2022, 14, 1063.	2.0	3
236	Association of High Ratio of CSF/Plasma HIV-1 RNA with Central Nervous System Co-Infection in HIV-1-Positive Treatment-Naive Patients. <i>Brain Sciences</i> , 2022, 12, 791.	1.1	1
237	Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e33429.	1.2	0
238	Dolutegravir plus rilpivirine: benefits beyond viral suppression. <i>Medicine (United States)</i> , 2022, 101, e29252.	0.4	6
239	Electroanalytical sensors for antiretroviral drugs determination in pharmaceutical and biological samples: A review. <i>Journal of Electroanalytical Chemistry</i> , 2022, 920, 116621.	1.9	5
240	Long-Term Persistence of Mitochondrial DNA Instability in HIV-Exposed Uninfected Children during and after Exposure to Antiretroviral Drugs and HIV. <i>Biomedicines</i> , 2022, 10, 1786.	1.4	2
241	The Clinic trials of Human Immunodeficiency Virus. , 0, 8, 523-528.		0
242	Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency. <i>Retrovirology</i> , 2022, 19, .	0.9	6
243	Cell-based and cell-free firefly luciferase complementation assay to quantify Human Immunodeficiency Virus type 1 Rev-Rev interaction. <i>Virology</i> , 2022, 576, 30-41.	1.1	0
244	The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9866.	1.8	30
245	Causes and outcomes of hepatic fibrosis in persons living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 359-367.	1.5	4

#	ARTICLE	IF	CITATIONS
246	The Potential of Moringa oleifera to Ameliorate HAART-Induced Pathophysiological Complications. Cells, 2022, 11, 2981.	1.8	2
247	Chronic delta-9-tetrahydrocannabinol (THC) treatment counteracts SIV-induced modulation of proinflammatory microRNA cargo in basal ganglia-derived extracellular vesicles. Journal of Neuroinflammation, 2022, 19, .	3.1	3
248	The prospects for the use of drugs based on the phenomenon of RNA interference against HIV infection. Voprosy Virusologii, 2022, 67, 278-289.	0.1	0
249	Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. Xenobiotica, 2022, 52, 541-554.	0.5	1
250	Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study. Annals of Translational Medicine, 2022, 10, 1125-1125.	0.7	0
251	Nanodelivery of antiretroviral drugs to nervous tissues. Frontiers in Pharmacology, 0, 13, .	1.6	2
252	Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and PBMC. Aids, 0, Publish Ahead of Print, .	1.0	2
253	The effects of HIV and the antiretrovirals on the mitochondria. , 2023, , 351-378.		0
254	Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review. Journal of Clinical Neuromuscular Disease, 2022, 24, 75-79.	0.3	2
255	Anti-retroviral treatment with zidovudine alters pyrimidine metabolism, reduces translation, and extends healthy longevity via ATF-4. Cell Reports, 2023, 42, 111928.	2.9	7
256	Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting. BMC Microbiology, 2023, 23, .	1.3	3
257	Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic. Viruses, 2023, 15, 322.	1.5	3
258	Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEHIV cohort study. Lancet HIV, the, 2023, 10, e164-e174.	2.1	4
259	A review on synthesis of antiviral drugs, in silico studies and their toxicity. Journal of the Indian Chemical Society, 2023, 100, 100936.	1.3	1
260	Whole-brain MR spectroscopic imaging reveals regional metabolite abnormalities in perinatally HIV infected young adults. Frontiers in Neuroscience, 0, 17, .	1.4	0
261	Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir. AIDS Research and Therapy, 2023, 20, .	0.7	4
262	Anti-HIV drugs reduce risk of prediabetes and progression to type 2 diabetes in HIV-infected patients. , 2023, 2, .		0
263	Moringa oleifera Lam Leaf Extract Stimulates NRF2 and Attenuates ARV-Induced Toxicity in Human Liver Cells (HepG2). Plants, 2023, 12, 1541.	1.6	2

#	ARTICLE	IF	CITATIONS
275	Pathogenic mechanisms of human immunodeficiency virus (HIV)-associated pain. <i>Molecular Psychiatry</i> , 2023, 28, 3613-3624.	4.1	0
285	Pathogenesis of HIV-associated pain. , 2024, , 95-115.		0
286	Antiretroviral therapy and its cerebral vascular toxicity. , 2024, , 567-594.		0